Acrivon Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD for Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Acrivon Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate for Q1 2024.
  • Acrivon Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was -$172K.
  • Acrivon Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was -$1.55M, a 102% decline from 2022.
  • Acrivon Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $102M, a 9.37% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$172K Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.